Comparison of Kidney Transplant Function, Lipid Metabolism Disorders, and Glucose and Hemoglobin Concentration in Transplant Patients Treated With Proliferation Signal Inhibitor (Everolimus) or Calcineurin Inhibitor (Tacrolimus)

Transplant Proc. 2020 Oct;52(8):2347-2351. doi: 10.1016/j.transproceed.2020.02.122. Epub 2020 Apr 16.

Abstract

Introduction: After kidney transplantation (KTx) in patients with diagnosed cancers, calcineurin inhibitor tacrolimus (TAC) is replaced by sirolimus or everolimus (EV).

Objective: The objective of the study was to compare the lipid metabolism parameters, KTx function, and glucose and hemoglobin (Hgb) levels in patients treated with EV to those on TAC.

Material and methods: The retrospective study included 114 patients: 54 (17 women and 37 men) aged 57.6 years (18-77 years) treated with EV and 60 (18 women and 42 men) aged 49.6 years (20-77 years) treated with TAC as a control group. Their total cholesterol (TC), triglycerides (TG), fasting glucose (FG), serum creatinine (SCr), Hgb, and estimated glomerular filtration rate (eGFR) were assessed. In the patients treated with EV, the above values were evaluated before conversion, as well as 12 and 24 months following the switch and were evaluated once in the group treated with TAC.

Results: In the EV-treated group, the mean preconversion values after 12 and 24 months were as follows: TC 5.06, 6.59, and 5.98 mmol/L; TG 1.90, 2.48, and 2.20 mmol/L; FG 94.95, 97.85, and 104.05 mg/dL; SCr 1.46, 1.44, and 1.56 mg/dL; Hgb 12.46, 12.83, and 13.36 g/dL; and eGFR 50.3, 50.6, and 50.5 mL/min/1.73 m2. In the patients on TAC, the authors obtained the following values: TC 4.6 mmol/L; TG 1.87 mmol/L; glucose 104.13 mg/dL; SCr 1.51 mg/dL; Hgb 13.96 g/dL; and eGFR 56.6 mL/min/1.73 m2.

Conclusions: After conversion from TAC to EV, increased values of TC and TG were observed after 1 year, while the increased values of TC, TG, SCr, Hgb, and FG were observed after 2 years.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Blood Glucose / drug effects
  • Calcineurin Inhibitors / adverse effects*
  • Creatinine / blood
  • Everolimus / adverse effects*
  • Female
  • Glomerular Filtration Rate
  • Graft Rejection / chemically induced
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Kidney Transplantation*
  • Lipid Metabolism / drug effects
  • Lipid Metabolism Disorders / chemically induced
  • Male
  • Middle Aged
  • Postoperative Period
  • Retrospective Studies
  • Sirolimus / adverse effects
  • Tacrolimus / adverse effects*
  • Triglycerides / blood
  • Young Adult

Substances

  • Blood Glucose
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Triglycerides
  • Everolimus
  • Creatinine
  • Sirolimus
  • Tacrolimus